Findings

What do systematic reviews say?

9 questions · 10 findings · 2 reviews · Skin · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 50%GRADE not reported 0 · 0%Very low 3 · 30%Low 0 · 0%Moderate 2 · 20%High 0 · 0%

Intralesional pentoxifylline vs daily simple dressing

Primary outcome: prevention of ulcer · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intralesional pentoxifylline vs daily simple dressing

Ulcer healing · ulceration and other skin changes caused by nerve damage in leprosy

It is very uncertain whether intralesional pentoxifylline changes primary outcome: healing of ulcer (complete healing of ulcer at 4… compared with daily simple dressing (very low certainty).

2 findings from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
OR 9 [1.64, 49.45]
1 study · 40 participants
Very low
Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Intralesional pentoxifylline vs daily simple dressing

Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Intralesional pentoxifylline vs daily simple dressing

Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intralesional pentoxifylline vs daily simple dressing

Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intralesional pentoxifylline vs daily simple dressing

Cost of the intervention · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate (IMMA) (20 mg/ kg /day for 20 days) vs IMMA plus placebo

Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 0.86 [0.63, 1.18]
1 study · 70 participants
Moderate

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate (IMMA) (20 mg/ kg /day for 20 days) vs IMMA plus placebo

Adverse effects · People with American cutaneous leishmaniasis

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Moderate

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate (IMMA) (20 mg/ kg /day for 20 days) vs IMMA plus placebo

Recurrence ‐ not measured · People with American cutaneous leishmaniasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found